苯扎贝特改善2型糖尿病合并高甘油三酯血症患者胰岛素抵抗的临床分析(1)
摘要：目的 探討苯扎贝特对2型糖尿病合并高甘油三酯血症患者降低血脂，同时改善胰岛素敏感性的影响及作用机制。方法选取我院2016年12月～2018年2月收治的符合入选标准2型糖尿病合并高甘油三酯血症患者56例，随机分为A组(n=29)和B组(n=27)。两组均使用苯扎贝特及非诺贝特降脂治疗，其他常规服用药物不变。A组：治疗顺序为苯扎贝特+非诺贝特，疗程各1个月，期间清洗期为1周;B组：治疗顺序为非诺贝特+苯扎贝特，疗程各1个月，期间清洗期为1周。监测两组患者实验前、第一阶段及第二阶段的甘油三酯(TG)、胆固醇、空腹血糖(FBG)、糖化血红蛋白(HbA1c)、空腹胰岛素(FINS)，并计算胰岛素敏感指数(IsI)。结果 两组患者实验前、第一阶段和第二阶段的TG和胆固醇水平比较，差异无统计学意义(P>0.05)。两组实验前和第一阶段的FBG、HbA1c及IsI比较，差异无统计学意义(P>0.05);B组第二阶段的FBG高于A组[(6.73±0.28)mmol/L vs (6.52±0.51)mmol/L]，HbA1c和IsI均低于A组[(6.54±0.32)% vs (6.76±0.71)%，(-4.19±0.34)vs(-4.13±0.28)]，差异有统计学意义(P<0.05)。结论 苯扎贝特可改善血脂，调节糖代谢，降低2型糖尿病患者血糖，并能改善胰岛β细胞分泌功能，提高机体胰岛素敏感性。
, http://www.100md.com
关键词：2型糖尿病;高甘油三酯血症;苯扎贝特;非诺贝特;胰岛素抵抗
Abstract：Objective To investigate the effect and mechanism of bezafibrate on reducing blood lipids and improving insulin sensitivity in patients with type 2 diabetes mellitus complicated with hypertriglyceridemia.Methods A total of 56 patients with type 2 diabetes mellitus complicated with hypertriglyceridemia who were admitted to our hospital from December 2015 to February 2018 were randomly divided into group A (n=29) and group B (n=27).Both groups were treated with bezafibrate and fenofibrate lipid-lowering drugs， and other conventional drugs were unchanged. Group A： The order of treatment was bezafibrate + fenofibrate， the time course was 1 month， and the cleaning period was 1 week; Group B： the treatment order was fenofibrate + bezafibrate， and the time course was 1 month.The period of cleaning is 1 week. Triglyceride (TG)， cholesterol， fasting blood glucose (FBG)， glycosylated hemoglobin (HbA1c)， fasting insulin (FINS)， and insulin sensitivity index (IsI) were calculated before， during the first and second phases of the two groups.Results There were no significant differences in TG and cholesterol levels between the two groups before， during the first and second phases (P>0.05). There was no significant difference in FBG， HbA1c and IsI between the two groups before and after the experiment (P>0.05). The FBG in the second stage of group B was higher than that in group A [(6.73±0.28) mmol/L vs (6.52±0.51)mmol/L]， HbA1c and IsI were lower than group A [(6.54±0.32)% vs (6.76±0.71)%， (-4.19±0.34) vs (-4.13±0.28)]， the difference was statistically significant (P<0.05).Conclusion Bezafibrate can improve blood lipids， regulate glucose metabolism， reduce blood sugar in patients with type 2 diabetes， improve the secretion function of islet β cells， and improve insulin sensitivity., 百拇医药(赵猛 孙娟 褚璇)
, http://www.100md.com
关键词：2型糖尿病;高甘油三酯血症;苯扎贝特;非诺贝特;胰岛素抵抗
Abstract：Objective To investigate the effect and mechanism of bezafibrate on reducing blood lipids and improving insulin sensitivity in patients with type 2 diabetes mellitus complicated with hypertriglyceridemia.Methods A total of 56 patients with type 2 diabetes mellitus complicated with hypertriglyceridemia who were admitted to our hospital from December 2015 to February 2018 were randomly divided into group A (n=29) and group B (n=27).Both groups were treated with bezafibrate and fenofibrate lipid-lowering drugs， and other conventional drugs were unchanged. Group A： The order of treatment was bezafibrate + fenofibrate， the time course was 1 month， and the cleaning period was 1 week; Group B： the treatment order was fenofibrate + bezafibrate， and the time course was 1 month.The period of cleaning is 1 week. Triglyceride (TG)， cholesterol， fasting blood glucose (FBG)， glycosylated hemoglobin (HbA1c)， fasting insulin (FINS)， and insulin sensitivity index (IsI) were calculated before， during the first and second phases of the two groups.Results There were no significant differences in TG and cholesterol levels between the two groups before， during the first and second phases (P>0.05). There was no significant difference in FBG， HbA1c and IsI between the two groups before and after the experiment (P>0.05). The FBG in the second stage of group B was higher than that in group A [(6.73±0.28) mmol/L vs (6.52±0.51)mmol/L]， HbA1c and IsI were lower than group A [(6.54±0.32)% vs (6.76±0.71)%， (-4.19±0.34) vs (-4.13±0.28)]， the difference was statistically significant (P<0.05).Conclusion Bezafibrate can improve blood lipids， regulate glucose metabolism， reduce blood sugar in patients with type 2 diabetes， improve the secretion function of islet β cells， and improve insulin sensitivity., 百拇医药(赵猛 孙娟 褚璇)